bioRxivCancer BiologyPreprint
GATA3-extension mutants rewire lineage identity in luminal breast cancer
Nivedhya Venas, Mrunal Ratnaparkhi, Kartik MajilaiD, Stacey Jamieson, Igor V. ChernukhiniD, Shruthi ViswanathiD, Jason S. CarrolliD, Dimple NotaniiD, Radhakrishnan SabarinathaniD
Abstract
GATA3, one of the most frequently mutated transcription factors in breast cancers, is a master regulator of luminal epithelial identity. Unlike many truncating and splice-site GATA3 mutations that disrupt one of the two zinc finger DNA-binding domains, C-terminal extension mutations (eGATA3) retain both of them. This raises the question of whether the eGATA3 mutants can alter transcriptional regulation and thereby exert distinct functional effects. Here, we integrate patient tumor-derived transcription and chromatin accessibility profiling with cell line derived genome-wide mapping of GATA3 occupancy and single-cell multiomics to define the regulatory consequences of eGATA3. We show that eGATA3 is associated with poor clinical outcome and remodels the luminal transcriptional program, leading to attenuation of estrogen-responsive transcription and progressive loss of luminal differentiation. Mechanistically, eGATA3 maintains widespread chromatin occupancy but redistributes GATA3 binding across different classes of regulatory elements, with preferential loss at AP-1 motif-enriched sites and gain at FOX-associated enhancers, along with coordinated remodeling of chromatin accessibility. These changes rewire the luminal regulatory landscape, destabilizing lineage identity without inducing complete lineage conversion. Together, our findings identify eGATA3 as a mechanistically distinct class of GATA3 mutation that promotes lineage plasticity through redistribution of genomic occupancy rather than loss of DNA-binding function alone.
- organism: human
- assay: bulk RNA-seq
- assay: ATAC-seq
- assay: scRNA-seq
- research focus: chromatin & epigenetic regulation
- research focus: cell type annotation
- approach: statistical model
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A class of GATA3 mutation reprograms the breast cancertranscriptional network through gain and loss of function
M. Takaku, S. A. Grimm, … P. A. Wade·bioRxiv·Oct 16, 2017
- GATA3 mutation disrupts a functional network governed by estrogen receptor, FOXA1 and GATA3
Motoki Takaku, Sara A. Grimm, … Paul A. Wade·bioRxiv·May 30, 2019
- The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
N. Hruschka, M. Subijana, … P. Martinelli·bioRxiv·Jun 8, 2019
- Mammary-specific ectopic expression of mutant human GATA3 did not potentiate medroxyprogesterone acetate-driven mouse mammary tumorigenesis
K. A. Lofgren, P. A. Kenny·bioRxiv·Jan 3, 2023
- Coordinate Enhancer Reprogramming by GATA3 and AP1 Promotes Phenotypic Plasticity to Achieve Breast Cancer Endocrine Resistance
- MLL3 adaptor function, not methyltransferase catalytic activity, is essential for breast tumor suppression
Kenta Nishitani, Jihong Cui, … Wenjun Guo·bioRxiv·Jun 8, 2026